Search
  • nzm0066

CDC's COVID-19 Booster Recommendation

Yesterday, CDC’s independent Advisory Committee on Immunization Practices (ACIP) recommended certain populations receive a booster shot of Pfizer-BioNTech’s COVID-19 Vaccine at least six months after the completion of their Pfizer vaccine primary series. In addition, the CDC Director recommended a booster dose for those in high risk occupational and institutional settings.


CDC recommends:

  • People 65 years and older and residents in long-term care settings should receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series;

  • People aged 50 to 64 with certain underlying medical conditions should receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series;

  • People 18 to 49 who are at high risk for severe COVID-19 due to certain underlying medical conditions may receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series, based on their individual benefits and risks; and

  • People aged 18-64 years who are at increased risk for COVID-19 exposure and transmission because of occupational or institutional setting may receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series, based on their individual benefits and risks.

The FDA’s and ACIP’s recommendations apply only to the Pfizer-BioNTech COVID-19 Vaccine with Moderna and Johnson & Johnson’s booster recommendations under review in the upcoming weeks.


https://www.cdc.gov/media/releases/2021/p0924-booster-recommendations-.html

23 views0 comments

Recent Posts

See All

Medicare Open Enrollment Begins Today!

Open enrollment for Medicare health and drug plans began today! Now is a wonderful opportunity to encourage your patients who are currently enrolled in Medicare Advantage and/or prescription drug plan

COVID-19 Booster Billing Codes Issued

The National Community Pharmacists Association (NCPA) has updated its COVID-19 vaccine billing and reimbursement handout to reflect the changes in the National Council for Prescription Drug Programs'